Rapt Therapeutics (RAPT)
(Delayed Data from NSDQ)
$1.76 USD
0.00 (0.00%)
Updated Sep 24, 2024 04:00 PM ET
After-Market: $1.80 +0.04 (2.27%) 6:58 PM ET
3-Hold of 5 3
F Value F Growth B Momentum F VGM
Brokerage Reports
0 items in cart
Rapt Therapeutics [RAPT]
Reports for Purchase
Showing records 1 - 20 ( 77 total )
Company: Rapt Therapeutics
Industry: Medical - Biomedical and Genetics
We Await RPT193 Analysis-Slated to Conclude in 3Q24; Reiterate Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Rapt Therapeutics
Industry: Medical - Biomedical and Genetics
Downsized Operations; We Await Clarity on Zelnecirnon; Reiterate Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Rapt Therapeutics
Industry: Medical - Biomedical and Genetics
RPT193 Phase 2 Trials Closed; 1Q24 Financials; Reiterate Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Rapt Therapeutics
Industry: Medical - Biomedical and Genetics
Our Thoughts on Tivumecirnon + Keytruda Data in HNSCC; Reiterate Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Rapt Therapeutics
Industry: Medical - Biomedical and Genetics
Awaiting Zelnecirnon Regulatory Clarity; 2023 Financials; Reiterate Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Rapt Therapeutics
Industry: Medical - Biomedical and Genetics
FDA Clinical Hold Creates Zelnecirnon Uncertainty; Downgrading to Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Rapt Therapeutics
Industry: Medical - Biomedical and Genetics
FDA Clinical Hold Creates Zelnecirnon Uncertainty; Downgrading to Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Rapt Therapeutics
Industry: Medical - Biomedical and Genetics
Major RPT193 Phase 2b Atopic Dermatitis Catalyst in Mid-2024; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Rapt Therapeutics
Industry: Medical - Biomedical and Genetics
Positive FLX475 + Keytruda Combo Data at SITC; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Rapt Therapeutics
Industry: Medical - Biomedical and Genetics
All Eyes on RPT193 Atopic Dermatitis Program; 2Q23 Financials; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Rapt Therapeutics
Industry: Medical - Biomedical and Genetics
FLX475 Biomarker Data Supports Efficacy Profile; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Rapt Therapeutics
Industry: Medical - Biomedical and Genetics
Further FLX475 Data Approaches in 2H23; 1Q23 Financials; Lowering PT to $41
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Rapt Therapeutics
Industry: Medical - Biomedical and Genetics
RPT193 Phase 2a Asthma Study Initiated; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Rapt Therapeutics
Industry: Medical - Biomedical and Genetics
Competitor Atopic Dermatitis Data Does Not Change Thesis; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Rapt Therapeutics
Industry: Medical - Biomedical and Genetics
RPT193 Phase 2 Data Pushed to Mid-2024; 2022 Financials; Modulating PT to $43; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Rapt Therapeutics
Industry: Medical - Biomedical and Genetics
Encouraging Activity for FLX475 at ESMO IO; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Rapt Therapeutics
Industry: Medical - Biomedical and Genetics
FLX475 Data Slated For ESMO-IO; 3Q22 Financials; Modulating PT to $50
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Rapt Therapeutics
Industry: Medical - Biomedical and Genetics
RPT193 Mid-Stage Programs; 2Q22 Financial Results; Raising PT to $53
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Rapt Therapeutics
Industry: Medical - Biomedical and Genetics
RPT193 Phase 2 Trial Initiation; 1Q22 Financial Results; Reiterate Buy; PT Down to $50
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Rapt Therapeutics
Industry: Medical - Biomedical and Genetics
Healthcare Coverage Update - Dropping Coverage
Provider: Roth Capital Partners, Inc.
Analyst: Research Department